Oral AL01211 for untreated men with Fabry disease
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study tests an oral medication called AL01211 for men who have classic Fabry disease but have never been treated before. The goal is to see if it is safe and if it can help reduce the build-up of fatty substances in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male and between 18 and 60 years old.
- You must have never received any previous Fabry disease treatments.
- You must have at least one symptom of Fabry disease (such as nerve pain, stomach issues, or kidney or heart problems).
- You need to have a genetic test confirming Fabry disease or be willing to have one.
- Your kidney function must be at least 50 mL/min/1.73 m2 (measured by a blood test).
- You must be willing to attend study visits and follow the study rules for about a year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether agalsidase alfa can reduce heart inflammation in people with Fabry disease who have heart problems. You may qualify if you have not had this treatment in the past year.
This trial tests a new gene therapy called AMT-191 for men with classic Fabry disease who still have symptoms despite standard enzyme replacement therapy. It aims to see if the treatment is safe and can improve symptoms.
This study tests an enzyme replacement therapy (agalsidase alfa) for Fabry disease in Chinese children and adults. It's an observational study that follows patients who receive the treatment as part of their regular care.
This trial is testing a new enzyme replacement therapy called Fabagal for people with Fabry disease who have not had prior treatment. It aims to see if it helps with kidney, heart, or brain problems caused by the disease.
This study tests a new medicine called lucerastat to see how well it works and how safe it is. It is for adult men with Fabry disease who have not been treated before. The medicine may help reduce the buildup of fatty substances in cells and improve symptoms.
This study looks at how well available Fabry disease treatments (like migalastat or ERT) work over time in real life. It may help doctors understand who benefits most from these medicines.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.